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Abstract
Objective—To harmonize the collection of nonsurgical clinical and epidemiologic data relevant 
to endometriosis research, allowing large-scale collaboration.
Design—An international collaboration involving 34 clinical/academic centers and three industry 
collaborators from 16 countries on five continents.
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Setting—In 2013, two workshops followed by global consultation, bringing together 54 leaders 
in endometriosis research.
Patients—None.
Intervention(s)—Development of a self-administered endometriosis patient questionnaire 
(EPQ), based on [1] systematic comparison of questionnaires from eight centers that collect data 
from endometriosis cases (and controls/comparison women) on a medium to large scale 
(publication on >100 cases); [2] literature evidence; and [3] several global consultation rounds.
Main Outcome Measure(s)—Standard recommended and minimum required questionnaires to 
capture detailed clinical and covariate data.
Result(s)—The standard recommended (EPHect EPQ-S) and minimum required (EPHect EPQ-
M) questionnaires contain questions on pelvic pain, subfertility and menstrual/reproductive 
history, hormone/medication use, medical history, and personal information.
Conclusion(s)—The EPQ captures the basic set of patient characteristics and exposures 
considered by the WERF EPHect Working Group to be most critical for the advancement of 
endometriosis research, but is also relevant to other female conditions with similar risk factors 
and/or symptomatology. The instruments will be reviewed based on feedback from investigators, 
and–after a first review after 1 year–triannually through systematic follow-up surveys. Updated 
versions will be made available through http://endometriosisfoundation.org/ephect.
Keywords
Endometriosis; EPHect EPQ; pelvic pain; questionnaire; standardization; symptoms
It is generally accepted that endometriosis is a heterogeneous disease with respect to its 
natural history, disease burden, extent of inflammation, state of progression, and phenotypic 
presentation of lesions and symptoms. The variability of patient “types” included in 
endometriosis research studies is not solely determined by the surgical characterization of 
the (extent of) disease during laparoscopy (1). There are important nonsurgical aspects that 
characterize patient (sub)populations, including symptomatology (onset, duration, extent and 
severity of symptoms, comorbidity) and other nonsymptomatic phenotypes such as 
anthropometric characteristics, ethnicity, and reproductive and demographic factors. These 
are important to consider in any endometriosis research study, and it may be that the 
inclusion of different patient populations in studies, which cannot be adequately defined or 
recognized as they have been poorly characterized, has led to conflicting results between 
studies of different populations (2).
To study phenotypic variation in endometriosis successfully, studies need to include 
sufficient numbers of patients to allow for the detection of differences between 
subphenotype groups with adequate statistical power. Collaboration and pooling of 
individual participant data across research centers can enable much larger sample sizes, can 
afford subgroup analyses, and is more effective than meta-analyses (3). However, data are 
often not collected in a manner that allows them to be prospectively or retrospectively 
compared. For example, in a study attempting to retrospectively pool epidemiologic data 
from 53 large population-based studies of > 10,000 individuals, part of the P3G 
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collaborative network (www.p3gobservatory.org), 47% of the variables studied were 
impossible to match (4). Given the variation in quality and complexity of the data collected 
across disparate centers, data pooling may not always be feasible, which can impede 
scientific progress. Moreover, standardization and harmonization of phenotypic data and 
biologic sample collection methods are crucial to allow meaningful comparison between 
different patient populations and (ethnic) groups in endometriosis research, and will aid the 
scientific inquiry into the etiology and pathogenesis of the disease. Indeed, successful, field-
altering risk-factor and subphenotype investigations among many centers have been 
demonstrated by large consortia across an array of health outcomes (5–11).
The mission of the World Endometriosis Research Foundation (WERF) Endometriosis 
Phenome and Biobanking Harmonisation Project (EPHect) is to develop a consensus on 
standardization and harmonization of phenotypic surgical/clinical data and biologic sample 
collection methods in endometriosis research. Specifically, to facilitate large-scale 
internationally collaborative, longitudinal, epidemiologically robust, translational, biomarker 
and treatment target discovery research in endometriosis, WERF EPHect provides evidence-
based guidelines on [1] detailed surgical, clinical, and epidemiologic phenotyping 
(phenome) data to be collected from women with and without endometriosis to allow 
collaborative subphenotype discovery and validation analyses; and [2] standard operating 
procedures (SOPs) for the collection, processing, and long-term storage of biologic samples 
from women with and without endometriosis. To the best of our knowledge, this 
harmonization initiative is unique in terms of its scope–addressing standardization of 
phenotypic data collection and biologic sampling protocols simultaneously for a specific 
disease–with a consensus reached among a large number of academic as well as industry 
leaders in endometriosis research. It also is a direct answer to the key priority of phenome 
data collection and SOP harmonization identified in Endometriosis Research Directions 
workshops held in 2008 (12) and 2011 (2) and will allow the investigation of a substantial 
number of other priorities highlighted.
In this report, we describe the development of an evidence-based, participant self-
administered questionnaire for research purposes developed by the EPHect Working Group 
to capture nonsurgical clinical phenomic data relevant to endometriosis research. Three 
companion papers cover the other EPHect end points. Our previous paper in this series 
focused on standardization of the surgical phenome data collection in women undergoing 
laparoscopy (1), while two further reports will discuss the development of SOPs for 
acquisition, processing, and long-term storage of biologic fluid (13) and tissue (14) to enable 
molecular phenome investigations. We envisage that the integrated use of the EPHect 
phenomic data collection instruments together with the adoption of the biologic sample 
SOPs will for the first time allow large-scale, robust, highly collaborative research into 
(subtypes of) endometriosis and its associated symptoms–including elucidation of its 
etiology, the discovery of noninvasive biomarkers of biologically different disease entities, 
and the development of novel, targeted, treatments (2).
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MATERIALS AND METHODS
We conducted two workshops in March 2013 and July 2013 that brought together leaders in 
endometriosis research worldwide to develop and reach consensus on evidence-based 
EPHect phenome collection and SOP guidelines, followed by several rounds of expert 
review by the WERF EPHect Working Group (Fig. 1). During Workshop I, four areas of 
standardization and harmonization were defined: [1] surgical phenotyping, [2] nonsurgical 
clinical/epidemiologic phenotyping, [3] and fluid sample and [4] tissue sample collection, 
processing, and storage protocols for molecular and genetic phenotyping. To date, the 
WERF EPHect global initiative has involved 34 clinical/academic centers and three industry 
collaborators (54 participants) from 16 countries on five continents. The WERF EPHect 
initiative, participants, and work flow are described in more detail in our first paper in this 
series on standardization of surgical phenome data collection (1).
The initial development of the nonsurgical patient questionnaire was based on questionnaire 
tools provided by eight centers around the globe that have collected nonsurgical information 
from endometriosis cases and controls on a large scale (criterion: publication on > 100 
cases). During Workshop I, their questionnaires were reviewed, and key topics were 
identified for inclusion in the EPHect endometriosis patient questionnaire (EPQ), including 
pelvic pain, subfertility and reproductive history, menstrual history and hormone use, 
medical and surgical history, medication use, and personal information. A subsequent e-mail 
consultation round including open invitations was sent to all 54 EPHect collaborators, 
asking them to review the EPHect EPQ under development and to participate in WERF 
EPHect Workshop II (London, 11 July 2013).
We conducted an extensive literature search in PubMed for English language publications 
describing associations between the key topics included in the EPHect EPQ and 
endometriosis. Rigorous review of the phrasing and temporality of each question on the 
EPhect EPQ was performed by the clinical and epidemiologic experts in the EPHect 
working group. Importantly, the EPHect EPQ development focused on selecting questions 
and rating scales that are validated in the literature, as described in this article. In addition, 
most questions were piloted by patients and volunteers in the centers contributing the 
questions, and all questions were reviewed by the workshop participants for face validity. 
During Workshop II, the questionnaire was presented to participants together with a 
summary of reviews obtained through e-mail consultation, and a consensus was obtained on 
the final content and format of the questionnaire (Supplemental Appendix 1, available 
online).
The development of the EPHect EPQ focused on information that was considered by the 
Working Group to be universally important to endometriosis centers in characterizing 
patients by their spectrum of symptoms. We did not include many potentially important 
exposures that may be associated with endometriosis etiologically and that may be of 
specific interest to some centers but were not considered crucial for patient characterization. 
These include, for example, nevi and freckles, sun exposure, in utero exposures, and others 
exposures (15). Investigators adopting the EPHect EPQ are encouraged to add any 
additional questions they would like to further their own scientific aims.
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As described for the development of the surgical data collection instrument (1), the EPHect 
Working Group recognized that there are likely to be differences in resources and logistics 
among centers that may mean they are unable to adhere to some of the strictest standards of 
data collection and SOP implementation. EPHect therefore agreed on two tiers for all data 
collection instruments as well as for biologic sample SOPs: standard recommended and 
minimum required. All participants in the consultation were asked to decide which 
information in the EPHect EPQ should be collected as a minimum (EPQ-M) requirement 
and which would be recommended as standard (EPQ-S), and a consensus on this division 
was achieved during Workshop II.
Approval by an ethics committee or institute review board was not required for formation of 
the EPHect Working Group, review of existing literature, or consensus regarding best 
practices for endometriosis research described within the WERF EPHect four manuscript 
series. This endeavor did not include data from human subjects. A comprehensive list of 
declared conflicts of interest for each of the authors and members of the EPHect Working 
Group is provided.
RESULTS
Supplemental Appendix 1 provides the consensus standard EPHect endometriosis patient 
questionnaire (EPHect EPQ-S), with sections excluded from the minimum version (EPHect 
EPQ-M) highlighted. These sections focus on symptoms or characteristics pertaining across 
the life course. We would argue that life course data are important to characterize women 
with and without endometriosis, particularly in the study of endometriosis which is marked 
by diagnostic delay (16, 17), but these are considered of secondary importance in settings 
where it is anticipated that completion of the EPHect EPQ-S will impact study recruitment 
because of its length. However, we stress that pilot work in several EPHect centers has 
shown that in both paper and electronic form the full standard questionnaire requires 25 to 
40 minutes to complete. We will discuss the development of each of the subsections of the 
EPHect EPQ-S.
Pain
Women with endometriosis experience a variety of pain symptoms, most commonly 
dysmenorrhea, noncyclical pelvic pain, dyspareunia, and dyschezia. However, the 
relationship between endometriosis and pain symptoms is complex, with little correlation 
between the extent of disease seen at laparoscopy and the severity of pain experienced by 
the patient (18, 19). As with many other disorders that involve visceral pain, it has become 
apparent that there are a variety of different mechanisms by which pain could be generated 
in endometriosis (Fig. 2) (20), potentially producing discrete “pain phenotypes,” even 
though our current understanding of these mechanisms is still fragmented. The pain section 
of the EPHect EPQ is designed to use validated measures to capture sufficient information 
to allow patients to be sub categorized on the basis of their pain symptoms.
The three main mechanisms generating pain are [1] nociceptive, [2] inflammatory, and [3] 
neuropathic or centrally generated pain, although it is likely that a combination of these 
processes occurs in many patients. It is plausible that these phenotypes may be characterized 
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by different biomarker profiles or may be responsive to specific treatments only, and 
therefore a failure to correctly characterize the pain symptoms may obscure a significant 
result in such studies. Furthermore, both psychological and cognitive factors can modulate–
in either a facilitatory or inhibitory manner–the pain experience, and they may also need to 
be considered (Fig. 3) (21).
Recommendations have been published for standard endometriosis–associated pain data 
collection techniques (22). Using these guidelines, the EPHect Working Group agreed that 
pain intensity will be measured on an 11-point numerical rating scale (NRS) anchored with 
0 = no pain and 10 = worst imaginable pain. Pain affect is captured on the EPHect EPQ with 
the short form McGill Pain Questionnaire (SF-MPQ). Though the original version of the SF-
MPQ is included on the EPHect EPQ in Supplemental Appendix 1, we strongly recommend 
as standard the use of the most recent SF-MPQ-2, as ratings are given on an 11-point scale, 
similar to the measures of pain intensity, and seven additional questions allow for the 
calculation of four separate domains (continuous pain, intermittent pain, neuropathic pain, 
and affective) and a total score as opposed to the original version which only calculates two 
domains (sensory and affective) and a total score (23). Use of the SF-MPQ-2 requires 
investigators to sign a user agreement, which is why we have not reproduced it in our 
questionnaire.
Of all the cognitive and psychological covariates commonly measured in experimental and 
clinical pain studies, pain catastrophizing (24) is repeatedly identified as the one robust 
measure associated with indices of pain sensitivity, clinical outcomes, and behavioral 
expressions of pain (25). Catastrophizing is defined currently as “an exaggerated negative 
mental set brought to bear during actual or anticipated painful experience” (26). However, 
its clinical relevance is perhaps easier to understand when considering the three subscales of 
the measure Rumination (“I can’t stop thinking about how much it hurts”), Magnification (“I 
worry that something serious may happen”), and Helplessness (“It’s awful, and I feel that it 
overwhelms me”), and the older definition of a catastrophizer as “an individual who has a 
tendency to magnify or exaggerate the threat value or seriousness of pain sensations” (27). 
As the pain catastrophizing scale is valid and relevant for both patients and healthy controls 
(referring to any pain experienced rather than to pelvic pain specifically), acceptable to 
patients/controls, and comprises of only 13 questions, we consider this to be an important 
covariate in interpreting other pain-related information and thus have included it in the 
EPHect EPQ. Although pain catastrophizing is considered a trait measure (25) and thus 
should not be influenced by the preceding questions, we recommend as a standard data 
collection protocol always placing these questions before the detailed pelvic pain history as 
presented in the questionnaire to minimize any systematic differences across centers.
Depression, Anxiety, and Health-related Quality of Life
Collection of information on psychological state and health-related quality of life in a 
symptom-based questionnaire can be important as these factors may affect responses related 
to symptomatology and therefore may be important in patient (symptomatic) stratification. 
We did not include validated measures of generic health status such as the Endometriosis 
Health Profile Questionnaire (EHP-30) (28) or the Short-Form Health Status Survey (SF-36) 
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(29) because these require registration and/or payment from the individual centers. 
Additionally, validated depression and anxiety scales that can be helpful for patient 
stratification include measures such as the Beck Depression Inventory (BDI) (30) and the 
State Trait Anxiety Inventory (STAI) (31), both of which are also considered valid for 
healthy controls. Alternatively, to save time and/or space, a combined measure such as the 
Hospital Anxiety and Depression Scale (HADS) (32) can be used, but it has been argued 
that this is more useful as a measure of overall psychological distress than for accurately 
determining the degree of anxiety and depression (33). We recommend that individual sites 
consider including these additional scales (Table 1) when they adopt the EPHect EPQ.
Menstrual History and Hormone Use
Age at menarche and menstrual cycle characteristics in the last 3 months are captured in 
detail on the questionnaire as they [1] have been robustly associated with endometriosis (34–
38), [2] are likely to influence symptom reporting, and [3] are crucial for interpretation of 
biologic assays. The EPHect EPQ-S includes a table on lifetime menstrual cycle 
characteristics while not on hormone medication, across different age ranges, which is not 
included in the EPHect EPQ-M. However, we highly recommend that these questions be 
asked as standard because early life menstrual cycle characteristics and their change over 
time may be important in the etiology of endometriosis.
The International Federation of Gynecology and Obstetrics (FIGO) recommendation for 
defining normal menstruation and menstrual cycle characteristics includes four parameters: 
regularity of menses, frequency of menses, and duration and heaviness of menstrual flow 
(39). We have followed the FIGO guidelines for capturing regularity, frequency, and 
duration of flow. The FIGO classification for volume of menstrual flow is heavy (>80 mL), 
normal (5–80 mL), and light (<5 mL), but this objective measurement of flow is beyond the 
scope of the EPHect EPQ. Therefore, we have classified menstrual flow as spotting, light, 
moderate, and heavy using a previously validated menstrual pictogram (40).
A complete history of hormone use is captured in the questionnaire, as this information is 
required to interpret reported symptomatology. In addition, long-term and recent hormone 
use can affect biomarker profiles (41–43), and it is therefore important to collect this 
information both to stratify subpopulations (e.g., endometriosis cases who use hormones for 
pain management) and to account for in biomarker research.
Subfertility and Reproductive History
Fertility impairments such as conception delay and infertility are associated with an 
endometriosis diagnosis (44), though whether endometriosis precedes these outcomes as 
well as what the relation is between causality and diagnostic bias are unknown. In fact, 
subfertility and endometriosis may have a common origin, as suggested by evidence linking 
in-utero exposures with endometriosis. Subfertility is assessed in the EPHect EPQ by the 
longest time (>6 months) a study participant has tried to become pregnant without success 
and any tests she might have had to find the cause of the sub-fertility. The standard 
definition of infertility is 12 months of regular unprotected intercourse without achieving a 
clinical pregnancy (45), and this definition can be derived from data collected with the 
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EPHect EPQ. However, as older women (such as women >35 years old) or women already 
known to have conditions that can lead to infertility might not try for 12 months before 
seeking medical intervention, 6 months was chosen as a screening cutoff. Additional 
questions relate to fertility advice sought, any type of infertility treatment received, and 
recency of this treatment. Some research aims involving infertility treatment will need 
additional medical record abstraction. For example, researchers focused on infertility 
treatment response will need to abstract data regarding ovarian stimulation protocol and 
response, fertilization, embryo culture, cohort characteristics, and transfer details from 
medical records because a self-administered questionnaire is not an appropriate method to 
accurately collect this information.
A detailed pregnancy history is captured in the EPHect EPQ, including age at the start of 
each pregnancy, type of fertility treatment used for each pregnancy, if applicable, and 
pregnancy outcome. Additional details for live births include whether the pregnancy was a 
multiple gestation, the type of delivery, and pregnancy complications. In prospective studies, 
increasing number of live births has been linearly associated with decreasing incidence of 
endometriosis (38). Retrospective studies have suggested that women with endometriosis 
may have higher rates of maternal complications and fetal problems such as preeclampsia 
and miscarriage (46–50), though these associations need further study.
Medical and Surgical History
Comorbidity is an important potential confounding factor in assessing symptom extent and 
severity. In the EPHect EPQ, participants are asked if they have ever been diagnosed (and at 
what age) with a list of ~30 medical conditions, including cancer, gynecologic diseases, pain 
syndromes, and autoimmune diseases, which have been (suggested to be) associated with 
endometriosis or its constituting symptoms in epidemiologic studies (51–54). Any 
occurrence of a structural problem/birth defect of the uterus, cervix, or vagina is also 
ascertained and whether it was surgically repaired because of the increased incidence of 
endometriosis in association with such anomalies (55). Surgical history (the age at each 
surgery, the type of surgery, and its indication) can be etiologically related to pelvic pain 
symptoms and impact on symptom reporting. These data may also provide an indication of 
the diagnostic path women suffering from pelvic pain or subfertility have experienced. Self-
reported medical history has been reported to be reliable and valid (56, 57).
Additionally, women are asked about recent bowel and urinary symptoms. To capture bowel 
symptoms that are common in women with endometriosis, we have included questions from 
the Rome III criteria irritable bowel syndrome module (58). Women with endometriosis 
experience bowel and urinary symptoms that are also associated with the menstrual phase 
(59, 60), and these are important to capture for defining case subpopulations.
A diagnostic history for endometriosis is canvassed in detail, including age at first 
symptoms, age and method of diagnoses, and any prior surgical treatments. A family history 
of endometriosis or of chronic pelvic pain is also obtained, while recognizing that accuracy 
of diagnosis has varied across generations.
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Medication Use
Collecting information on recent medication use is important for biomarker research as 
some drugs may interact with the biomarkers to be studied and may thus distort the results. 
Although the medication use assessment in the patient questionnaire does not capture recent 
use in detail, our companion reports on biologic fluids and tissue collection and processing 
(13, 14) contain a biospecimen collection tool developed to capture medication use in the 30 
days and 48 hours before specimen collection, including herbal medications. The purpose of 
the prescription medication and over-the-counter pain medication lists included in the EPQ 
is to capture medication use that could have influenced how women respond to questions or 
highlight patterns of use (for example, sleeping aids) that are more prevalent among women 
with endometriosis or with pain symptoms relative to those without. Medications for chronic 
pain or inflammatory conditions or for other symptoms, such as depression or anxiety, may 
affect pain reporting. Moreover, experimental data suggest that anti-inflammatory drugs 
may affect the severity of the disease (61, 62).
Personal Information
The demographic data that are required for interpretation of any epidemiologic study result 
include age, race/ethnicity, major ancestry, and highest level of education attained, and are 
collected on the EPHect EPQ. Race/ethnicity is assessed with categories previously used in 
a worldwide study (63). However, we realize these categories may not sufficiently capture 
all populations where this questionnaire will be used. Investigators using the questionnaire 
are permitted to alter or add categories as they see fit, but we request that any changes still 
allow categories to be collapsed to their current form to ensure that cross-study data 
harmonization will continue to be possible.
The anthropometric exposures captured are body mass index (BMI; current height and 
weight), most and least weighed since age 18, somatotype by age range (64), and body 
shape by age range (65). Current BMI has been shown to be inversely associated with 
endometriosis (66) and validly measured by self-reported questionnaire (67–69). Greater 
body size and adolescent weight have both been shown to be associated with a decreased 
risk of endometriosis (66, 70). Two questions on hair and eye color, previously associated 
with endometriosis (71–75) and possibly useful in marking genetic subpopulations, are also 
included.
Basic questions on three lifestyle covariates are included in the questionnaire: smoking, 
alcohol use, and exercise. Smoking and alcohol use, which have been associated with 
endometriosis in a prospective study (76), are captured as former and current smoking and 
packs per day as well as current number of alcoholic drinks per week. Recent physical 
activity is assessed as the average time spent per week during the past year on various 
activities, allowing for the calculation of metabolic equivalent (MET) scores. The 
reproducibility and validity of self-administered questionnaires on adult physical activity 
were examined in a prospective cohort and found to be appropriate for epidemiologic 
research (77).
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DISCUSSION
To facilitate collaboration among endometriosis researchers that is not stymied by 
incompatible data collection, we encourage researchers worldwide to adopt the EPHect 
EPQ. The questionnaire can be completed by any woman undergoing investigation for 
symptoms of endometriosis (whether she has the disease or not), or asymptomatic women, 
subject to signed written informed consent obtained from each patient and local ethics 
approval for the study according to ethical principles for clinical research summarized in the 
Declaration of Helsinki. To enable the multicenter collaborations, envisaged by the WERF 
EPHect initiative, it is essential that centers adopting the WERF EPHect instruments and 
SOPs ensure that patients provide informed consent that allows their data and biologic 
samples to be used in future multicenter (inter)national collaborations, and that appropriate 
ethics committee and institute review board approval is obtained that allows for such 
collaborations. Additionally, individual sites and their institutional review boards will need 
to determine whether systems should be in place to flag specific responses to any question 
for urgent local clinical review.
The EPQ is not designed for use in clinical practice to inform immediate clinical decisions. 
Many physicians ask patients to complete questionnaires that they have been designed ad 
hoc for their clinical practices, and some may find portions of the EPQ to be of interest for 
that purpose. However, the questionnaire was not designed to accommodate in-clinic 
completion and immediate review, as this is beyond the scope and inconsistent with the 
goals of EPHect. Additionally, to our knowledge, none of the longstanding, validated 
component parts of the EPQ have been applied in an immediate point-of-care setting. 
Individual physicians and their institutional review boards will need to determine what, if 
any, data they would like to include in the clinical record. This would be equally true for 
results from discovery testing conducted using the biologic samples collected in compliance 
with EPHect protocols.
The EPHect EPQ captures details on pain, menstrual and reproductive history, medical 
history, hormone use and infertility, and demographics and lifestyle characteristics and is 
sufficient to capture the minimum nonsurgical clinical phenome in endometriosis cases and 
controls. The exposures and characteristics assessed in the questionnaire were included 
because they have all been associated with endometriosis in published literature. Although 
the questionnaire is freely available, we request that researchers who use it cite it 
appropriately and explicitly state in publications any alterations they have made to it.
One central aim of WERF EPHect is to standardize phenotypic data collection across studies 
of endometriosis. This standardization will promote large-scale research using multiple data 
sets that are characterized using the same phenotypic definitions and will simplify 
interpretation of concordant or discordant results among data sets. We believe that the 
EPHect EPQ is the most up-to-date tool for capturing the nonsurgical clinical and 
epidemiologic phenome specific to endometriosis and its accompanying symptoms and 
strongly advise the EPQ-S be adopted where possible.
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The evidence base for all EPHect data collection instruments and SOPs will be reviewed 
continuously upon feedback provided by investigators, and through systematic surveys and 
follow-up reviews after 1 year and every 3 years thereafter. Thus, investigators are strongly 
encouraged to provide such feedback. Updates of instruments will remain freely accessible 
to the research community through the EPHect website (endometriosisfoundation.org/
ephect). In addition, the EPHect Working Group will develop supplemental modular 
questionnaires that can be added to the standard questionnaire as requested by individual 
investigators or as scientific evidence in new or developing areas emerges. These additional 
modules will be reviewed and validated by the EPHect team and approved by WERF for 
public dissemination through the website.
In the next phase of the EPHect initiative, WERF aims to [1] develop freely available stand-
alone applications as well as web-based systems to facilitate center-restricted data entry and 
reduce costs and time expenditure to individual centers, and [2] amalgamate a voluntary 
registry of centers using EPHect data collection tools and biologic sample SOPs that would 
offer any investigator a transparent platform for the establishment of new collaborations. We 
ask that publication of results that are generated using WERF EPHect data and sample 
collection protocols appropriately reference the sources, including version numbers, of the 
instruments used.
In conclusion, the EPHect Working Group stresses that the development of the EPHect EPQ 
and the systems to administer it are driven by a collective pursuit of advancing our 
understanding of endometriosis, facilitating diagnosis and treatment development, and 
ultimately advancing disease prevention strategies through global cooperation (1). The 
EPHect EPQ is a critical and necessary data collection tool designed with the input of 
leaders in endometriosis research worldwide to achieve the goal of facilitating large-scale 
cross-center, longitudinal, epidemiologically robust, biomarker and treatment target 
discovery research in endometriosis. If adopted by research centers across the globe, the 
EPHect EPQ will aid in the design and conduction of large, multicenter, geographically 
diverse studies with high reliability and validity, conducted on behalf of the millions of girls 
and women struggling with endometriosis and its associated symptoms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Flow diagram depicting the WERF EPHect development and consensus process (clinical 
data collection).
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FIGURE 2. 
Mechanisms by which the nervous system can be engaged in endometriosis (17). 
Endometriotic lesions appear to be able to engage the nervous system throughout the 
neuroaxis. In addition to developing their own innervation [both peptidergic sensory (blue) 
and sympathetic nerve fibers (green)], all nerve fibers within the pelvis may become 
sensitized (red asterisk), as may the central nervous system. The extent of peripheral 
sensitization is dynamically modulated by estradiol and sympathetic-sensory coupling, and 
other factors may modulate central sensitization.
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FIGURE 3. 
Factors influencing nociceptive inputs to affect pain perception (18). A variety of factors 
modulate incoming signals such that the experience of pain is not linearly related to the 
nociceptive input.
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TABLE 1
Additional validated generic health status and depression/anxiety scales, not included in the EPHect EPQ, that 
should be considered by individual centers.
Generic health status
  Endometriosis Health Profile Questionnaire (EHP-30)
  Short-Form Health Status Survey (SF-36)
Depression and anxiety
  Beck Depression Inventory (BDI)
  State Trait Anxiety Inventory (STAI)
  Hospital Anxiety and Depression Scale (HADS)
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